Literature DB >> 15998647

Oxalate clearance by haemodialysis--a comparison of seven dialysers.

Casper F M Franssen1.   

Abstract

BACKGROUND: In patients with primary hyperoxaluria (PH) and oliguric end-stage renal disease, oxalate removal is largely dependent on the clearance by dialysis. Data on the oxalate clearance of newer dialyser types are scarce or absent. Therefore, we measured oxalate clearances of seven dialysers in a single 52-year-old female patient with PH. Since haemodiafiltration (HDF) has been advocated to increase oxalate clearance, we also assessed the effect of different pre-dilution flows. The goal of the study was to select the dialyser and pre-dilution flow combination with the highest oxalate clearance.
METHODS: Oxalate clearances were assessed by simultaneously taking afferent blood and efferent dialysate samples at 30, 60, 120 and 180 min after the start of haemodialysis. Blood flow and dialysate flow were 350 and 500 ml/min, respectively. All dialysers were tested at a pre-dilution flow of 2 l/h. Six dialysers were also tested at either a pre-dilution flow of 4.5 l/h or without HDF, depending on the ultrafiltration coefficient of the dialyser.
RESULTS: Oxalate clearances differed markedly between the tested dialysers, ranging from 144+/-10 to 220+/-12 ml/min. The highest oxalate clearances were achieved with HdF100S (219+/-10 ml/min) and Sureflux FB-210U (220+/-12 ml/min) at a pre-dilution flow of 2 l/h. Higher pre-dilution flows (2 l/h vs no HDF or 4.5 vs 2.0 l/h) yielded similar oxalate clearances.
CONCLUSION: The highest oxalate clearances were achieved with a high-flux polysulfone and a cellulose triacetate dialyser with a large surface area. Higher pre-dilution flows did not augment oxalate clearance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15998647     DOI: 10.1093/ndt/gfh971

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Kidney failure in a transplant from an identical twin.

Authors:  Erik L Lum; John M Morton; Marc L Melcher
Journal:  Am J Kidney Dis       Date:  2013-08       Impact factor: 8.860

Review 2.  Update on oxalate crystal disease.

Authors:  Elizabeth C Lorenz; Clement J Michet; Dawn S Milliner; John C Lieske
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

3.  The association of calcium oxalate deposition in kidney allografts with graft and patient survival.

Authors:  Ragnar Palsson; Anil K Chandraker; Gary C Curhan; Helmut G Rennke; Gearoid M McMahon; Sushrut S Waikar
Journal:  Nephrol Dial Transplant       Date:  2020-05-01       Impact factor: 5.992

4.  Intra-operative continuous renal replacement therapy during combined liver-kidney transplantation in two patients with primary hyperoxaluria type 1.

Authors:  Casper F M Franssen; Ido P Kema; Douglas J Eleveld; Robert J Porte; Jaap J Homan van der Heide
Journal:  NDT Plus       Date:  2011-02-10

5.  The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels.

Authors:  Esmée M Ettema; Judith Heida; Niek F Casteleijn; Lianne Boesten; Ralf Westerhuis; Carlo A J M Gaillard; Ron T Gansevoort; Casper F M Franssen; Debbie Zittema
Journal:  Kidney Int Rep       Date:  2017-01-23

6.  Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.

Authors:  Theresa Ermer; Christoph Kopp; John R Asplin; Ignacio Granja; Mark A Perazella; Martin Reichel; Thomas D Nolin; Kai-Uwe Eckardt; Peter S Aronson; Fredric O Finkelstein; Felix Knauf
Journal:  Kidney Int Rep       Date:  2017-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.